The stock of Can-Fite BioPharma Ltd. (NYSE:CANF) is now priced at $2.23 and the shares are -0.03 points down or -1.33% lower compared to its previous closing price of $2.26. The stock had 1.371 million contracts set over the past session. CANF shares’ daily volume is compared to its average trading volume at 1.603 million shares. However, it has a float of 9.81 million and although its performance was 2.29% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the CANF share price recently placing at $2.2 to $2.5. However, some brokerage firms have priced the stock below the average, including one that has called $5.

The shorts are running away from the Can-Fite BioPharma Ltd. stock, with the latest data on short interest released on July 31, 2020, showing that short interest numbers in the CANF shares have declined. Short interest in the stock represents just 4.45% of its float, but the volume has dropped by 0.

In the last trading session, Can-Fite BioPharma Ltd. (NYSE:CANF) raised by $0.05 over the week and lost -$0.23 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $4.95. The stock recorded its established 52-week high on 12/02/19.

Since 02/12/20, the stock has traded to a low of $1.08 at 106.48%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge.

Looking at current readings, Can-Fite BioPharma Ltd.’s two-week RSI is 47.71. This suggests that the stock is neutral at the moment and that CANF shares’ price movement remains stable. The stochastic readings are equally revealing at 27.48% meaning the CANF share price is currently in overbought territory.

The technical chart shows that the CANF stock will likely settle at between $2.42 and $2.61 per share. However, if the stock dips below $2.12, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $2.01.

Currently, the stock is trading in the red of MACD, with a reading of -0.04. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

Analysts at Maxim Group assigned CANF a rating of Buy in their intiating review released on August 11. ROTH Capital analysts see the stock as a Buy in a flash note released to investors on October 19 resuming covering the stock. Rodman & Renshaw analysts see the stock as Buy when the analysts resumed the share price coverage on August 29, placing it at $6.

The average rating for the CANF equity is 2 and is currently gathering a bullish momentum. Of 2 analysts tracking Can-Fite BioPharma Ltd. polled by Reuters, 0 rated CANF as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.

Zacks Consensus Estimate forecasts that the current-quarter revenues for Can-Fite BioPharma Ltd. (NYSE:CANF) will decrease by about -63.9%, which will see them reach $250 million. The company’s full-year revenues are, however, expected to increase by about 46698.03%, up from $2.03 million to $950 million. CANF’s expected adjusted earnings should drop almost -74.02% to end up at -$0.33 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -46.97% to record -$1.75/share.